Lloyd Czaplewski

Biography

Dr. Czaplewski has >25-years of biopharmaceutical and NCE discovery and development experience from concept to clinical evaluation across multiple therapeutic areas – including anti-infective indications. He has built and then sold an antibacterial company, hired outstanding teams, created SABs and has raised >£25M from UK, Europe, USA and Japan including charities (Wellcome Trust), Government (DTI, UK & NIAID, USA), Corporate (Astellas) and VC investment groups. He is an inventor on >25 patents and has authored > 30 papers. He is currently the Founder and CEO of Abgentis Ltd which focuses on semi-synthetic aminocoumarin antibiotics; CSO of Persica Pharmaceutical Ltd which focuses on chronic back pain, and a Founder and Director of Chemical Biology Ventures Ltd which provides consulting services to biotech, academia, charities and investors. He recently chaired a review into Alternatives to Antibiotics for Wellcome and the Department of Health which informed the O’Neill Report and is involved in several antibiotic R&D initiatives including GARDP and its Antimicrobial Memory Recovery Initiative, Antibiotic Research UK, The Pew Trust’s Antibiotic Resistance Project and as a member of a CARB-X interview panel. Over the last 15 years, Lloyd has led the tendering process, contracting and project management of multiple antibacterial programmes through a variety of CROs e.g. microbiology (Evotec, Amtuit, LGC, Wuxi), in vitro ADMET (Cyprotex), pharmacology (Evotec, GVK Biosciences, Wuxi), Efficacy (Evotec, Wuxi, University of North Texas (Bill Weiss)), Formulation (Kuecept, Aptuit, Quay, Onyx, Critical Pharmaceuticals), medicinal chemistry and scale up to kilo lab (Evotec, Jubilant Chemsys, Key Organics, Biofocus, Aptuit, GVK Biosciences, Sai Advantium, SYNthesis Med Chem) and where necessary has developed key assays in house to inform optimisation programmes e.g. photostability, phototoxity and protein binding.

Research Interest

Drug metabolism